COMP <GO>
MED vs WMT // 10Y YIELD & FRED MACRO BETA
MEDIFAST INC (NYSE) VS. Walmart Inc. (NYSE) • 15-METRIC TALLY: MED 1
— WMT 10
■ METRIC PARITY
LAST: $12.15 (-0.90%) • MKT CAP: $137.1M
macro-sensitivity
—
LAST: $123.51 (+1.86%) • MKT CAP: $961.97B
macro-sensitivity
0.57
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MED VS. WMT)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | MED | WMT | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 71.30% | 25.23% | +46.07 | MED | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -10.20% | 20.14% | -30.34 | WMT | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 22.5x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 0.91% | 1.39% | -0.48 | WMT | /fcf-yield <GO> |
| Operating Margin | -3.70% | 4.39% | -8.09 | WMT | /operating-margins <GO> |
| Net Profit Margin | -4.90% | 3.00% | -7.90 | WMT | /net-margins <GO> |
| Revenue Growth (YoY) | -36.00% | 6.16% | -42.16 | WMT | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.14% | 0.80% | -0.66 | WMT | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 4.71 | 6.23 | -1.52 | WMT | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 7/9 | -2.00 | WMT | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 6.38% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 56.7 | 57.7 | -1.00 | WMT | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta ACTIVE | — | 0.57 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 39.4x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $137.1M | $961.97B | -$961.83B | WMT | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | MED REV | WMT REV | MED GROSS % | WMT GROSS % | MED FCF | WMT FCF |
|---|---|---|---|---|---|---|
| FY 2026 | — | $713.16B | — | 24.9% | — | $14.92B |
| FY 2025 | $385.8M | $680.99B | 71.3% | 24.9% | $1.2M | $12.66B |
| FY 2024 | $602.5M | $648.13B | 73.8% | 24.4% | $17.0M | $15.12B |
| FY 2023 | $1.07B | $611.29B | — | 24.1% | $147.7M | $11.98B |
| FY 2022 | — | $572.75B | — | 25.1% | — | $11.07B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MED // BETA —
WMT // BETA 0.57